MA46466A - Formulations pharmaceutiques de protéines à viscosité réduite - Google Patents
Formulations pharmaceutiques de protéines à viscosité réduiteInfo
- Publication number
- MA46466A MA46466A MA046466A MA46466A MA46466A MA 46466 A MA46466 A MA 46466A MA 046466 A MA046466 A MA 046466A MA 46466 A MA46466 A MA 46466A MA 46466 A MA46466 A MA 46466A
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical formulations
- reduced viscosity
- proteins
- viscosity proteins
- reduced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404861P | 2016-10-06 | 2016-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46466A true MA46466A (fr) | 2019-08-14 |
Family
ID=60294396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046466A MA46466A (fr) | 2016-10-06 | 2017-10-06 | Formulations pharmaceutiques de protéines à viscosité réduite |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11459401B2 (fr) |
| EP (1) | EP3522918A1 (fr) |
| JP (2) | JP7275027B2 (fr) |
| MA (1) | MA46466A (fr) |
| WO (1) | WO2018067987A1 (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017000527A (es) * | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
| MX388858B (es) | 2014-10-23 | 2025-03-20 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
| WO2017210360A1 (fr) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Procédés de diagnostic et de traitement du lupus érythémateux disséminé |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| JP7377596B2 (ja) * | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| WO2019147824A1 (fr) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de pde4 |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
| EP3810095A1 (fr) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf |
| WO2019246317A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme |
| WO2019246273A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un jak ou un autre inhibiteur de kinase |
| WO2019246312A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un immunomodulateur |
| WO2019246271A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur d'il-12/il-23 |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020071876A1 (fr) * | 2018-10-04 | 2020-04-09 | 삼성바이오에피스 주식회사 | Trastuzumab à concentration élevée ayant une viscosité réduite ou agent de stabilisation de fragment de liaison à l'antigène associé |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| PH12022550167A1 (en) * | 2019-08-16 | 2023-05-08 | Regeneron Pharma | High concentration anti-c5 formulations |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| CN111024863A (zh) * | 2019-12-31 | 2020-04-17 | 上海博威生物医药有限公司 | 一种雷莫芦单抗的肽图的测试方法 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| BR112022026670A2 (pt) * | 2020-07-13 | 2023-01-24 | Merck Patent Gmbh | Excipientes de redução da viscosidade e combinações dos mesmos para formulações de proteína altamente concentradas |
| EP4243793A4 (fr) | 2020-11-10 | 2024-10-02 | Medregen, LLC | Préparations, procédés, nécessaires et formes posologiques |
| CA3204307A1 (fr) * | 2020-12-17 | 2022-06-23 | Astrazeneca Ab | Formulations d'anticorps anti-il5r |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2024257040A1 (fr) * | 2023-06-14 | 2024-12-19 | Enzene Biosciences Limited | Composition et formulations liquides stables comprenant des anticorps monoclonaux humanisés anti-récepteurs de l'interleukine 6 humaine (il-6) |
| CN120405149A (zh) * | 2025-06-23 | 2025-08-01 | 美康生物科技股份有限公司 | 一种肝素结合蛋白检测试剂盒 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| PL217752B1 (pl) | 2001-08-23 | 2014-08-29 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| US8871712B2 (en) | 2005-01-14 | 2014-10-28 | Camurus Ab | Somatostatin analogue formulations |
| JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5’修飾二環式核酸類似体 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| US20130072665A1 (en) | 2007-08-23 | 2013-03-21 | Simon Mark Jackson | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| WO2009131740A2 (fr) | 2008-04-23 | 2009-10-29 | Amgen Inc. | Variants neutralisants de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et ses applications |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
| JP5711138B2 (ja) | 2008-11-16 | 2015-04-30 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 高濃度の低粘度懸濁液 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2493507A4 (fr) | 2009-10-30 | 2013-11-20 | Merck Sharp & Dohme | Antagonistes et variants ax213 et ax132 pcsk9 |
| KR101614983B1 (ko) | 2009-11-17 | 2016-04-22 | 입센 파마 에스.에이.에스 | Hgh 및 rhigf―1의 조합물을 위한 제제 |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| JP2014514275A (ja) | 2011-03-10 | 2014-06-19 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | タンパク質ナノ粒子分散系 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| AU2013262611B2 (en) * | 2012-05-18 | 2018-03-01 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
| US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| EP3193928A1 (fr) * | 2014-08-06 | 2017-07-26 | Rinat Neuroscience Corp. | Méthodes destinées à réduire le cholestérol ldl |
| WO2016046684A1 (fr) * | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Traitement avec des anticorps anti-pcsk9 |
| MX388858B (es) | 2014-10-23 | 2025-03-20 | Amgen Inc | Reducción de la viscosidad de formulaciones farmacéuticas |
-
2017
- 2017-10-06 WO PCT/US2017/055620 patent/WO2018067987A1/fr not_active Ceased
- 2017-10-06 JP JP2019518478A patent/JP7275027B2/ja active Active
- 2017-10-06 EP EP17797203.1A patent/EP3522918A1/fr active Pending
- 2017-10-06 MA MA046466A patent/MA46466A/fr unknown
- 2017-10-06 US US16/337,325 patent/US11459401B2/en active Active
-
2023
- 2023-02-27 JP JP2023028743A patent/JP2023054369A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018067987A1 (fr) | 2018-04-12 |
| US11459401B2 (en) | 2022-10-04 |
| JP2023054369A (ja) | 2023-04-13 |
| JP2019530703A (ja) | 2019-10-24 |
| US20200024363A1 (en) | 2020-01-23 |
| JP7275027B2 (ja) | 2023-05-17 |
| EP3522918A1 (fr) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| EP3493799A4 (fr) | Composition pharmaceutique decannabis | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| EP3509581A4 (fr) | Formulations de (r | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| EP3493798A4 (fr) | Composition pharmaceutique decannabis | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| EP3454899C0 (fr) | Composition pharmaceutique | |
| EP3364944C0 (fr) | Compositions pharmaceutiques d'il-2 | |
| MA43705A (fr) | Formulation pharmaceutique | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| EP3603642A4 (fr) | Préparation pharmaceutique | |
| EP3429589A4 (fr) | Composition pharmaceutique du nilotinib | |
| EP3454847A4 (fr) | Formulations de médicaments améliorées | |
| EP3402470A4 (fr) | Composition pharmaceutique stable | |
| MA47516A (fr) | Composition pharmaceutique | |
| EP3512521A4 (fr) | Composition pharmaceutique de clozapine à libération prolongée | |
| EP3383371A4 (fr) | Formulation pharmaceutique | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| EP3646866A4 (fr) | Préparation pharmaceutique | |
| EP3582759A4 (fr) | Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3337463A4 (fr) | Formulations pharmaceutiques | |
| HUE069648T2 (hu) | Gyógyszerészeti készítmény |